Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference57 articles.
1. Diabetes and obesity: the twin epidemics
2. Islet cell failure in type 2 diabetes
3. Role of Reduced Suppression of Glucose Production and Diminished Early Insulin Release in Impaired Glucose Tolerance
4. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
5. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis;PLOS ONE;2016-05-09
2. Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications;Journal of Medicinal Chemistry;2014-11-13
3. How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment;Diabetes Care;2013-07-17
4. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis;Expert Opinion on Drug Safety;2013-04-27
5. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus;Clinical Interventions in Aging;2013-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3